Business Overview: DSS, Inc. (NYSE American: DSS)

---

Executive Summary

DSS, Inc. is a New York corporation headquartered in Henrietta, New York, operating as a diversified holding company across four reportable segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. The company generated roughly $20.8 million in fiscal 2025 revenue, up 9% year over year, with the large majority coming from its legacy printed-packaging business.

DSS matters less as a single focused operator and more as a conglomerate testing whether diversification into biotech licensing, commercial lending, and brokerage/real-estate services can be layered on top of a stable, cash-generating packaging and secure-document-printing core.

---

1. Core Business Model & How They Work

DSS's core, cash-generating engine is traditional packaging and secure document printing, with the other three segments functioning as separate, smaller financial and biotech ventures layered on top.

[ Packaging & Secure Printing (Premier Packaging) ] ➡️ [ Cash Flow ] ➡️ [ Capital Allocated To: Biotech Licensing, Commercial Lending, Brokerage/Real Estate ] ➡️ [ Diversified Segment Revenue ]

Key Operational Drivers

1. Legacy Packaging Core: Premier Packaging Corporation makes paperboard folding cartons, consumer packaging, mailers, and document security printing (prescription paper, vital records, secure coupons) for pharmaceutical, nutraceutical, food, beverage, and health/beauty customers.
2. Biotech Licensing Strategy: DSS BioHealth Security/Impact BioMedical pursue drug discovery and wellness products primarily through licensing and partnerships rather than in-house commercialization, holding 9 issued patents and over 40 pending worldwide.
3. Commercial Lending Arm: American Pacific Financial, Inc. offers commercial lines of credit, land development, and inventory/equipment financing, shifting away from direct marketing toward inventory/equipment lending and broker-dealer loans.
4. Securities & Real Estate: Sentinel Brokers (majority-owned, FINRA-registered broker-dealer), BMI Capital International (advisory), and AMRE (American Medical REIT) holding healthcare real estate round out the diversified model.

---

2. Business Segments

┌───────────────────────────────────────────┐
│                  DSS, Inc.                  │
└──────────────────────┬──────────────────────┘
                        │
   ┌────────────────────┼────────────────────┬──────────────────────┐
   ▼                    ▼                    ▼                      ▼
┌─────────────┐  ┌───────────────┐  ┌──────────────────┐  ┌──────────────────────┐
│ Product      │  │ Biotechnology  │  │ Commercial         │  │ Securities &          │
│ Packaging    │  │ (Licensing)    │  │ Lending             │  │ Investment Mgmt       │
│ (~87% of     │  │ (~0.2% of      │  │ (~0.2% of           │  │ (Sentinel, BMI,       │
│  revenue)    │  │  revenue)      │  │  revenue)           │  │  AMRE — ~12.5%)       │
└─────────────┘  └───────────────┘  └──────────────────────┘  └──────────────────────┘

Product Packaging (Premier Packaging)

Makes folding cartons, consumer packaging, mailers, and secure document printing (prescription paper, vital records, secure coupons) for pharma, nutraceutical, food/beverage, and health & beauty customers, mostly in the US. By far the largest revenue contributor.

Biotechnology (DSS BioHealth Security / Impact BioMedical)

Pursues licensing of drug-discovery and wellness candidates: LineBacker, Equivir, Procombin, VanXin, Bioplastics, Laetose (sugar alternative), 3F (insect repellent/antimicrobial), Quantum, and a Bio Med probiotic license. Revenue is currently minimal (~$38,000 in FY2025) and tied mainly to the Celios air purification brand.

Commercial Lending (American Pacific Financial)

Offers commercial lines of credit, land development, and inventory/equipment financing, with third-party loan servicing. Interest and fee income fell sharply in FY2025 (~$45,000).

Securities and Investment Management

Sentinel Brokers (majority-owned FINRA broker-dealer, ~$1.35 million commissions), BMI Capital International (corporate finance advisory), and AMRE (American Medical REIT, ~$1.24 million rental income from healthcare real estate).

---

3. Product Portfolio

---

4. Competitive Landscape

Product Packaging

Faces many national and regional competitors, most of them private. The 10-K names WestRock Company and Graphic Packaging Holding Company as major, much larger public competitors. Competition centers on price, quality, service, regulatory compliance, sustainability, and turnaround time.

Commercial Lending

Competes against traditional commercial banks and investment banks; no specific firms are named, reflecting the fragmented nature of niche commercial lending.

Biotechnology

Competes with other biotech firms and research institutions pursuing similar licensing and drug-discovery models; no specific competitors are named.

Securities and Investment Management

Competes with individual money managers, financial institutions, broker-dealers, REITs, private equity firms, and investment companies.

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Diversified cash-flow base: four distinct revenue streams reduce (in theory) reliance on any single industry's cycle.
• Patent portfolio in biotech: 9 issued and 40+ pending patents worldwide give Impact BioMedical real, if unproven, intangible-asset optionality.
• Regulated, licensed financial arms: Sentinel Brokers (FINRA/SIPC) and AMRE provide regulatory barriers that a casual competitor could not easily replicate.

Risks

• Customer concentration in packaging: one customer was ~29% of FY2025 consolidated revenue (two customers were 22% and 13% in FY2024).
• AMRE LifeCare loan default: about $37 million outstanding is in default, a material balance-sheet risk.
• Intangible asset impairment risk: ~$17.0 million of net intangible assets tied to Impact BioMedical depend on future licensing success.
• Internal control weaknesses: previously identified weaknesses could lead to misstatements or restatements.
• Ownership concentration: directors, officers, and 5%+ holders control about 68% of shares.
• Listing risk: possible NYSE American delisting and continued dilution from equity issuances.
• Litigation: a pending Texas lawsuit involves counterclaims from Puradigm LLC seeking over $1 million.

---

6. Financial Overview

---

7. Summary Conclusion

DSS, Inc. is best understood as a holding company whose real, dependable business is secure packaging and printing — a steady, if unglamorous, cash generator competing against much larger players like WestRock and Graphic Packaging. Its biotech, lending, and brokerage/real-estate segments add optionality and diversification but remain small and, in the case of the AMRE loan default, carry real balance-sheet risk. The company's path forward depends on whether packaging cash flow can continue funding these side ventures long enough for one (most plausibly the biotech licensing pipeline) to become a genuine second profit center, without the AMRE default or internal-control issues forcing a retrenchment first.